跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

S8626

Sigma-Aldrich

磺胺嘧啶

99.0-101.0%

别名:

N-2-嘧啶基-4-氨基苯磺酰胺, N1-(嘧啶-2-基)磺胺

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C10H10N4O2S
CAS号:
68-35-9
分子量:
250.28
Beilstein:
6733588
EC號碼:
200-685-8
MDL號碼:
MFCD00006065
分類程式碼代碼:
51283908
PubChem物質ID:
24899802
NACRES:
NA.85

描述

Solubility - Practically insoluble in water, slightly soluble in acetone, very slightly soluble in ethanol (96 per cent). It dissolves in solutions of alkali hydroxides and in dilute mineral acids.

品質等級

200

化驗

99.0-101.0%

形狀

powder or crystals

顏色

white to faint yellow, faint pink

mp

253 °C (dec.) (lit.)

溶解度

96% ethanol: very slightly soluble
acetone: slightly soluble
water: practically insoluble

抗生素活性譜

Gram-negative bacteria
Gram-positive bacteria
mycoplasma

作用方式

DNA synthesis | interferes
enzyme | inhibits

SMILES 字串

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

InChI 密鑰

SEEPANYCNGTZFQ-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

化学结构式：磺酰胺

應用

磺胺嘧啶是一种短效磺胺类药物，常用于与乙胺嘧啶合用治疗获得性免疫缺陷综合征患者的弓形虫病。也用于治疗新生儿先天性感染 。在研究再活化弓形虫病的鼠模型时，磺胺嘧啶已被用于控制急性感染 。

生化／生理作用

磺胺嘧啶是一种磺胺类抗生素，通过抑制二氢喋呤合成酶而阻断二氢叶酸的合成。磺胺嘧啶是细菌合成叶酸所需的对氨基苯甲酸 (PABA) 的竞争性抑制剂 。对革兰氏阳性菌、革兰氏阴性菌和衣原体有效。耐药模式是通过改变二氢喋呤合成酶或叶酸合成的替代途径。

其他說明

将容器密闭保存在干燥和通风良好的地方。储存类别 (TRGS 510)：非易燃固体

訊號詞

Warning

危險聲明

H302,H361d,H411

危險分類

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 2

個人防護裝備

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
069M4750V
069M4751V
029M4867V
128M4832V
098M4880V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sven Jechalke et al.
Applied and environmental microbiology, 79(5), 1704-1711 (2013-01-15)
Spreading manure containing antibiotics in agriculture is assumed to stimulate the dissemination of antibiotic resistance in soil bacterial populations. Plant roots influencing the soil environment and its microflora by exudation of growth substrates might considerably increase this effect. In this
Romain Sonneville et al.
Neurology, 79(17), 1762-1766 (2012-10-12)
Cerebral toxoplasmosis remains a common neurologic complication in patients with AIDS. In this study, we aimed to characterize the prognosis of patients with HIV infection with severe forms of cerebral toxoplasmosis and to investigate the effects of adjunctive steroids on
Tamim M Niazi et al.
International journal of radiation oncology, biology, physics, 84(3), e305-e310 (2012-06-02)
For patients with anal canal and advanced rectal cancer, chemoradiation therapy is a curative modality or an important adjunct to surgery. Nearly all patients treated with chemoradiation experience some degree of radiation-induced dermatitis (RID). Prevention and effective treatment of RID
Ildiko R Dunay et al.
Antimicrobial agents and chemotherapy, 53(10), 4450-4456 (2009-07-29)
Immunocompromised patients are at risk of developing toxoplasmosis, and although chemotherapy is available, standard treatments are often complicated by severe side effects. Artemisinin is a new highly potent antimalarial drug that has activity against Toxoplasma gondii in vitro. However, artemisinin
Pascale Meneceur et al.
Antimicrobial agents and chemotherapy, 52(4), 1269-1277 (2008-01-24)
Sulfadiazine, pyrimethamine, and atovaquone are widely used for the treatment of severe toxoplasmosis. Their in vitro activities have been almost exclusively demonstrated on laboratory strains belonging to genotype I. We determined the in vitro activities of these drugs against 17
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门